| Alternative Name: | Interleukin-17A, IL-17, CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8 |
| |
| MW: | Dimer, ~15.1/30.2 kDa |
| |
| Source: | Produced in E. coli. Contains 134/268 amino acids. |
| |
| UniProt ID: | Q62386 |
| |
| Formulation: | Lyophilized from a sterile (0.2 micron) filtered solution containing 0.1% Trifluoroacetic Acid (TFA). |
| |
| Purity: | ≥95% (SDS-PAGE) |
| |
| Endotoxin Content: | ≤1 EU/µg protein (LAL test) |
| |
| Biological Activity: | Production of IL-6 by mouse 3T3 cells; ED50≤5 ng/mL (≥2.0x105 units/mg). |
| |
| Reconstitution: | Reconstitute in sterile water at 0.1 mg/mL. |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | -80°C |
| |
| Handling: | Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and store at -80°C. For long term storage, it is recommended to dilute to working aliquots in a 0.1% BSA solution. |
| |
| Scientific Background: | Interleukin 17A (IL-17A), also known as CTLA-8, is a member of the IL-17 family of proteins. IL-17A is a pro-inflammatory cytokine that is secreted by activated CD4+ and CD8+ T lymphocytes. IL-17A acts through its receptor, IL-17R, to promote increased cytokine and chemokine secretion. Cytokines and chemokines then mediate the immunoregulatory function of IL-17A by promoting the proliferation, maturation, and chemoattraction of neutrophils to inflammatory sites. Elevated levels of IL-17A are associated with rheumatoid arthritis, airway inflammation, allograft rejection, inflammatory bowel disease, psoriasis, cancer, and multiple sclerosis. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
